Fri, 10/16/2020 – 15:30
Based on new data and advances, the International Antiviral Society–USA Panel has updated its guidelines related to antiretroviral therapy (ART) for people with HIV. A volunteer committee of 15 experts scrutinized evidence added to the scientific record since the 2018 recommendations were released. Through August of this year, they flagged 5,316 citations about antiretroviral drugs—549 of which were used to inform the revision. The 2020 document calls for ART to begin as soon as possible for anyone with detectable viremia, regardless of their CD4 cell count. Most patients can start with a three-drug cocktail, but new findings also support a combination of dolutegravir and lamivudine as well as novel long-acting injectable regimens administered every 4 weeks—or 8 weeks, pending regulatory approval and availability. The authors also expanded the guidance with a section on HIV management in older adults, in light of the fact that many HIV patients are now achieving normal life spans through ART. The revised document additionally touches on the dynamic between HIV and COVID-19, which has affected how HIV experts manage patients, conduct research, and more.